Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL)

Historical Holders from Q2 2020 to Q1 2025

Symbol
ZNTL on Nasdaq
CUSIP
98943L107
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
71.3M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
64.4M
Holdings value
$195M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
141
Number of buys
83
Number of sells
-52
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Walters William T 9.9% +8.89% $11.2M $874K 7.05M +8.46% Walters William T Jan 29, 2025
EVENTIDE ASSET MANAGEMENT, LLC 6.28% $7.11M 4.48M Eventide Asset Management, LLC Dec 31, 2024
MILLENNIUM MANAGEMENT LLC 5.3% $6.01M 3.78M Millennium Management LLC Jan 29, 2025
VANGUARD GROUP INC 4.59% $5.2M 3.27M The Vanguard Group Dec 31, 2024
FMR LLC 0.2% $280K 176K FMR LLC Nov 29, 2024

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 410K $652K -$40.3K $1.59 5
2024 Q4 64.4M $195M -$24.7M $3.03 141
2024 Q3 71M $261M -$21.7M $3.68 133
2024 Q2 76.6M $313M -$53.8M $4.09 142
2024 Q1 85.1M $1.34B +$58.3M $15.76 137
2023 Q4 81.1M $1.23B -$20.4M $15.15 117
2023 Q3 80M $1.61B -$51.6M $20.06 134
2023 Q2 82.1M $2.31B +$442M $28.21 129
2023 Q1 67M $1.15B +$45.9M $17.20 107
2022 Q4 64.3M $1.3B +$105M $20.14 103
2022 Q3 55.3M $1.2B -$49.4M $21.66 108
2022 Q2 58.1M $1.63B +$360M $28.10 112
2022 Q1 44.3M $2.04B +$46.9M $46.14 119
2021 Q4 42.8M $3.6B +$96.2M $84.06 131
2021 Q3 41.2M $2.75B +$112M $66.64 112
2021 Q2 39.4M $2.1B +$205M $53.20 116
2021 Q1 36.3M $1.58B -$55.2M $43.39 92
2020 Q4 36.9M $1.92B +$310M $51.94 101
2020 Q3 31.6M $1.03B +$170M $32.69 65
2020 Q2 26.9M $1.28B +$1.28B $48.02 61